HZ1 is an orally active first-in-class cyclin-dependent kinase like 3 (CDKL3) -specific inhibitor. HZ1 shows a strong tumor-suppressing effect, and has the potential to overcome the resistance of CDK4/6 inhibitor.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ser/Thr Protease
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.